{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.5","upperLimit":"78.7","value":"72.5"},{"groupId":"OG001","lowerLimit":"20.5","upperLimit":"33.7","value":"26.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"187"}],"units":"Participants"}],"description":"ORR is defined as the percentage of patients with a best overall response defined as complete response (CR) or or partial response (PR) measured by BIRC per RECIST 1.1. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ceritinib administered continuously through oral dosing at a dosage of 750 mg once daily in fasted state","id":"OG000","title":"Ceritinib"},{"description":"Pemetrexed plus cisplatin or carboplatin (based on Investigator's choice) for 4 cycles (Induction) followed by pemetrexed as single agent (Maintenance)","id":"OG001","title":"Chemotherapy"}],"paramType":"NUMBER","populationDescription":"The Full Analysis Set (FAS) consisted of all patients to whom study treatment had been assigned by randomization.","reportingStatus":"POSTED","timeFrame":"Up to approximately 34 months","title":"Overall Response Rate (ORR) by BIRC Assessment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}